• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Edoxaban.依度沙班
Hosp Pharm. 2015 Jul;50(7):619-34. doi: 10.1310/hpj5007-619. Epub 2015 Jul 31.
2
Netupitant/Palonosetron.奈妥匹坦/帕洛诺司琼
Hosp Pharm. 2015 Apr;50(4):310-25. doi: 10.1310/hpj5004-310. Epub 2015 Apr 8.
3
Ferric citrate.柠檬酸铁
Hosp Pharm. 2015 Feb;50(2):139-51. doi: 10.1310/hpj5002-139.
4
Cangrelor.坎格雷洛
Hosp Pharm. 2015 Nov;50(10):922-929. doi: 10.1310/hpj5010-922. Epub 2015 Nov 19.
5
Secukinumab.司库奇尤单抗
Hosp Pharm. 2015 Sep;50(8):714-27. doi: 10.1310/hpj5008-714. Epub 2015 Sep 16.
6
Dapagliflozin.达格列净
Hosp Pharm. 2014 Jul;49(7):647-62. doi: 10.1310/hpj4907-647.
7
Ceftolozane/Tazobactam.头孢洛扎/他唑巴坦
Hosp Pharm. 2015 Jun;50(6):526-33. doi: 10.1310/hpj5006-526.
8
Dalbavancin.达巴万星
Hosp Pharm. 2014 Oct;49(9):851-61. doi: 10.1310/hpj4909-851.
9
Ledipasvir/Sofosbuvir.来迪派韦/索磷布韦
Hosp Pharm. 2015 Mar;50(3):224-34. doi: 10.1310/hpj5003-224.
10
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.奥比他韦/帕利瑞韦/利托那韦和达沙布韦
Hosp Pharm. 2015 May;50(5):396-412. doi: 10.1310/hpj5005-396.

本文引用的文献

1
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.依度沙班对比华法林在伴有心房颤动和心力衰竭患者中的疗效和安全性:来自 ENGAGE AF-TIMI 48 的观察。
Eur J Heart Fail. 2016 Sep;18(9):1153-61. doi: 10.1002/ejhf.595. Epub 2016 Jun 28.
2
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.21105例心房颤动患者随机接受依度沙班或华法林治疗后的全身性、非脑性动脉栓塞:心房颤动-心肌梗死溶栓研究48试验中下一代Xa因子有效抗凝治疗的结果
Am Heart J. 2015 Oct;170(4):669-74. doi: 10.1016/j.ahj.2015.06.020. Epub 2015 Jul 2.
3
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.终末期肾病血液透析患者依度沙班的药代动力学、安全性和耐受性。
Thromb Haemost. 2015 Apr;113(4):719-27. doi: 10.1160/TH14-06-0547. Epub 2015 Jan 8.
4
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.依度沙班对经皮穿刺活检后出血的影响及 4 因子凝血酶原复合物浓缩物的逆转作用。
Circulation. 2015 Jan 6;131(1):82-90. doi: 10.1161/CIRCULATIONAHA.114.013445. Epub 2014 Nov 17.
5
Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.口服Xa因子抑制剂依度沙班与依诺肝素在全膝关节置换术后预防血栓形成方面的安全性和有效性:STARS E-3试验
Thromb Res. 2014 Dec;134(6):1198-204. doi: 10.1016/j.thromres.2014.09.011. Epub 2014 Sep 21.
6
Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.健康志愿者中依度沙班的群体药代动力学及剂量-暴露量比例关系
Clin Drug Investig. 2014 Oct;34(10):743-52. doi: 10.1007/s40261-014-0229-7.
7
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.日本和中国台湾地区全髋关节置换术后口服因子 Xa 抑制剂依度沙班的安全性和有效性研究。
J Arthroplasty. 2014 Dec;29(12):2439-46. doi: 10.1016/j.arth.2014.05.029. Epub 2014 Jun 9.
8
Edoxaban: an update on the new oral direct factor Xa inhibitor.依度沙班:新型口服直接凝血因子Xa抑制剂的最新进展。
Drugs. 2014 Jul;74(11):1209-31. doi: 10.1007/s40265-014-0261-1.
9
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.21105 例心房颤动随机分组至依度沙班与华法林治疗的脑血管事件:房颤患者中新型 Xa 因子抗凝剂的有效抗凝作用-心肌梗死溶栓 48 研究
Stroke. 2014 Aug;45(8):2372-8. doi: 10.1161/STROKEAHA.114.006025. Epub 2014 Jun 19.
10
Edoxaban: a focused review of its clinical pharmacology.依度沙班的临床药理学重点综述。
Eur Heart J. 2014 Jul 21;35(28):1844-55. doi: 10.1093/eurheartj/ehu181. Epub 2014 May 8.

依度沙班

Edoxaban.

作者信息

Cada Dennis J, Baker Danial E, Ingram Kyle

机构信息

Founder and Contributing Editor, The Formulary , Washington State University Spokane , Spokane, Washington.

Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane , Spokane, Washington.

出版信息

Hosp Pharm. 2015 Jul;50(7):619-34. doi: 10.1310/hpj5007-619. Epub 2015 Jul 31.

DOI:10.1310/hpj5007-619
PMID:26445907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4589853/
Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The July 2015 monograph topics are ivabradine, dinutuximab, glycopyrronium bromide/indacaterol, patriromer, and idarucizumab. The Safety MUE is on ivabradine.

摘要

《处方集专论服务》的订阅者每月会收到5至6篇关于新发布或处于3期临床试验后期阶段药物的详细专论。这些专论面向药学与治疗学委员会。订阅者每月还会收到关于对议程以及药房/护理在职培训有用药物的1页摘要专论。每月还会提供一份全面的目标药物利用评估/用药评估(DUE/MUE)。订阅后,专论会以印刷版形式发送,也可在线获取。专论可进行定制以满足机构的需求。现在每月会随《处方集专论服务》发布一次药物类别综述。通过《处方集》的合作,《医院药学》在本专栏发表精选综述。有关《处方集专论服务》的更多信息,请致电《处方集》800 - 322 - 4349。2015年7月专论主题为伊伐布雷定、地努图希单抗、格隆溴铵/茚达特罗、帕替罗姆和依达赛珠单抗。安全性MUE针对伊伐布雷定。